Drug Approval | December 23, 2025
FDA nod to MYQORZO for obstructive hypertrophic cardiomyopathy
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The drug is designed to improve functional capacity and reduce symptoms by inhibiting cardiac myosin motor activity
The platform aims to serve doctors, consumers, and healthcare facilities by providing AI-assisted clinical decision tools, personalized health insights, and improved diagnostic capabilities
The therapy also drove additional weight loss at the higher 1.8 mg dose without plateauing and maintained a favorable tolerability profile
The initiative is focused on a problem that continues to plague cancer outcomes in India
The seminar aimed to raise public awareness about inflammageing—chronic, low-grade inflammation that silently damages the body and accelerates ageing
The study is being conducted under a USFDA IND, has received U.S. Fast Track Designation for SLE-ITP, and has obtained IND approval from China’s Center for Drug Evaluation
Company acquires People Tree Hospital Yeshwanthpur for Rs. 430 crore
The approval for Exdensur (depemokimab-ulaa) comes on the back of SWIFT-1 and SWIFT-2 Phase III trials
The company operates a chain of mid-sized multi-speciality hospitals
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Subscribe To Our Newsletter & Stay Updated
